Alternatives to Moldova – Medical equipments – Achiziționarea protezelor valvulare și vasculare, inclusiv consumabile pentru anul 2027

Moldova – Medical equipments – Achiziționarea centralizată a Consumabilelor Medicale conform necesităților IMSP beneficiare pentru anul 2027

Poland – Pharmaceutical products – Dostawa produktów leczniczych wykorzystywanych przez oddziały szpitala, leki stosowane w ramach programów lekowych oraz chemioterapii (część 1)

Sweden – Personal care products – Extern Remiss Hygien och städmaterial 2025

Italy – Social work services – SUA PROV BG. PREFETTURA DI BG. SERVIZIO ACCOGLIENZA E ASSISTENZA CITTADINI STRANIERI RICHIEDENTI PROTEZIONE INTERNAZIONALE C/O CENTRI ART.11 D.LGS. 142/2015 UBICATI NEL TERRITORIO PROVINCIALE DI BG - SINGOLE UNITA' ABITATIVE CON CAPACITA' RICETTIVA MAX 50 POSTI PER STRUTTURA - TOTALE COMPLESSIVO DI N. 150 POSTI, PER LA DURATA TRIENNALE, INIZIO PRESUNTO DALLA DATA DI STIPULA.

Italy – Miscellaneous medical devices and products – Fornitura di dispositivi sterili in TNT (teli, camici e kit) per uso chirurgico e dispositivi medici in TNT ed accessori a corredo di kit chirurgici in TTR

Spain – Welfare services for children and young people – CONTRATACIÓN DE 74 PLAZAS DE ACOGIMIENTO RESIDENCIAL MENORES. MODALIDAD: VARIAS

Italy – Vascular prostheses – ENDOPROTESI VASCOLARI ADDOMINALI E (KIT EMERGENZE) III EDIZIONE

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: Project results are expected to contribute to all the following expected outcomes: Advance in the achievement of the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy; Efficient and effective support to wind energy research and innovation through alignment and cooperation among different actors, avoiding fragmentation of efforts; Energy producers and consumers benefit from increased performance of wind energy technologies with the focus on efficiency and flexibility, reduced cost, improved reliability and sustainability, operation and maintenance, safety, robustness and security during all stages of the lifetime of a wind energy farm from installation, operation and maintenance to decommissioning; Increased contribution of wind energy to the energy system, with minimal impacts on health and the environment (notably biodiversity and pollution) and at the lowest possible cost. Scope: The action contributes to address the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy, as defined by the Implementation Working Group (IWG) on wind energy, the European…

Sweden – Health and social work services – Drift av Vårdbostäderna Ekollongatan och Skräddaregården

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…